Boston Cell Standards Reaches Key Milestone with FDA in Cancer Diagnostics

Boston Cell Standards (BCS) has reached a pivotal stage in the FDA’s Medical Device Development Tools (MDDT) Program, marking a significant move towards standardizing cancer diagnostic assays. As the first company pursuing qualification for Immunohistochemistry (IHC) Reference Materials, this achievement could greatly enhance the reproducibility and accuracy of cancer diagnostics, ultimately impacting clinical trials and drug approvals.

BCS aims to transform clinical immunohistochemistry (IHC) testing across labs by introducing their IHC Reference Materials (IRMs). Historically, IHC assays have depended on random tissue samples, leading to variable results and error margins as high as 30%. By providing calibrated materials with defined biomarker concentrations, BCS aspires to reduce these inconsistencies, thereby improving the reliability of biomarker measurements essential for determining cancer treatment options. This advancement in the MDDT program reflects the FDA’s endorsement of BCS’s innovative approach for stabilizing and standardizing IHC assays, potentially streamlining the regulatory pathways for new cancer therapies.

Boston Cell Standards’ progress in the FDA’s MDDT Program could herald a new era for cancer diagnostic assays, offering a more consistent and objective standard for IHC testing. If successfully qualified, the BCS platform would not only elevate the quality of cancer diagnostics but also hasten the availability of new treatments, thus improving patient outcomes.